title: Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.
abstract: Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non-invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis, diagnosis and response to treatment. There is a need to develop cfDNA biomarkers to avoid complex risk-prone biopsy procedures for primary or metastatic tumors. Given the challenges associated with inter- and intra-tumor heterogeneity, the implementation of genome-wide cfDNA analysis will become an important avenue to understand tumor progression and therapeutic settings, not only for predominant, but also for under-represented tumor subclones with specific genomic aberrations. We summarize the latest publications in cfDNA analysis, including a metric analysis of clinical trials and new high-throughput technology applied to cfDNA analysis in clinical oncology.
authors.affiliation: Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA.
authors.forename: Diego M
authors.initials: DM
authors.lastname: Marzese
authors.forename: Hajime
authors.initials: H
authors.lastname: Hirose
authors.forename: Dave S B
authors.initials: DS
authors.lastname: Hoon
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood* / Q000737:chemistry / Q000235:genetics; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000097:blood* / Q000737:chemistry / Q000235:genetics; D055088:Early Detection of Cancer / Q000379:methods*; D006801:Humans; D009154:Mutation; D011237:Predictive Value of Tests; D017422:Sequence Analysis, DNA
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm